This study will test a new investigational product that may help with the treatment of OA pain in the knee, the improvement of knee joint function associated with OA, and potentially delay structural progression of OA disease.
Osteoarthritis (OA) is the most common disease of the joints, affecting more than 250 million people in the world. OA is characterized by a progressive cartilage breakdown, and the symptoms are pain, aching, stiffness and decreased function of joints such as the knees, hips or fingers.
The potential new treatment is called PTP-001 and is administered as a single injection into the knee of patients with OA for up to 6 months.
The study will take up to 7 months for you to complete during which time there will be 5-6 clinic visits to see the study doctor and at least 2 follow up calls.
Reimbursement for travel will be provided, and all study doctor visits will be free of charge.